Thrombin-JMI in TKA minimizes hemoglobin reduction but may not be cost effective .
Use of bovine thrombin to reduce blood loss in primary total knee arthroplasty: a controlled randomized trial
J Arthroplasty. 2013 Sep;28(8):1278-8180 osteoarthritic patients, aged 18 years and older, undergoing total knee arthroplasty were randomized to evaluate the efficacy of bovine thrombin (Thrombin-JMI), over 2 years, in improving blood loss parameters, total drain output, transfusion requirements, length of stay, bleeding related complications and Knee Society Scores (KSS), during and after surgery. The evidence presented in this study indicated that although the use of thrombin during TKA did slightly reduce blood loss, it did not significantly improve any other measured outcome, and therefore may not be a cost effective treatment for hemostasis in TKA patients with osteoarthritis.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
